A phase III randomized controlled trial is underway in Iran to assess the effectiveness of long-term, low-dose aspirin in preventing gastric cancer.

Spine BioPharma completed enrollment in its Phase 3 MODEL trial, evaluating SB-01 for chronic low back pain (CLBP) due to degenerative disc disease (DDD).

A pilot study suggests that anakinra, an IL-1 antagonist, may reduce dysmenorrhea pain scores in women with endometriosis.

A phase 2 trial (SHARP) indicates that combining radium-223 dichloride with stereotactic body radiation therapy (SBRT) and ADT is well-tolerated for mCSPC.

Puma Biotechnology has commenced the ALISCA™-Breast1 Phase II trial to evaluate alisertib combined with endocrine therapy for HR+/HER2- metastatic breast cancer.

Palatin Technologies has completed enrollment in its Phase 2 study of oral PL8177 for ulcerative colitis, with topline data expected in Q1 2025.

Puma Biotechnology has commenced the ALISCA™-Breast1 Phase II trial to evaluate alisertib combined with endocrine therapy for HR+/HER2- metastatic breast cancer.

A clinical trial is underway to compare the effects of two different doses of vitamin D3 in critically ill patients receiving continuous renal replacement therapy (CRRT).

Delcath Systems received FDA clearance for its IND application to initiate a Phase 2 trial of Hepzato Kit in liver-dominant metastatic colorectal cancer (mCRC).

The CHORMES study is a randomized, double-blind, placebo-controlled trial investigating mesoglycan for treating acute hemorrhoidal disease (HD).

Cytokinetics has commenced the COMET-HF trial, a Phase 3 study evaluating omecamtiv mecarbil in patients with symptomatic heart failure and severely reduced ejection fraction.

A pooled analysis of four clinical trials (n=576) evaluated the safety of belzutifan monotherapy in patients with renal cell carcinoma (RCC).

A study investigates imeglimin's impact on metabolic function using a two-step hyperinsulinemic-euglycemic glucose clamp, employing an artificial endocrine pancreas to maintain glucose levels.

Insilico Medicine has been recognized as a Fierce 50 honoree for its pioneering work in AI-driven drug discovery and development.

The FDA has granted De Novo marketing authorization to Healgen Scientific for its Rapid Check COVID-19/Flu A&B Antigen Test, the first OTC combination test.

Kineta has finished enrolling patients in the monotherapy phase of its Phase 1 VISTA-101 trial, which assesses KVA12123 in advanced solid tumors.

A mobile health (mHealth) intervention based on the Multi-Theory Model (MTM) significantly reduced anxiety and depression in patients with differentiated thyroid cancer (DTC).

Nurix Therapeutics has appointed Anil Kapur, a seasoned pharmaceutical executive, to its board of directors, effective October 15, 2024.

The FDA has granted accelerated approval to epcoritamab for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

A new enhanced titration dosing regimen of donanemab significantly reduced the frequency and severity of amyloid-related imaging abnormalities-edema (ARIA-E).